Current State of Bariatric Surgery - Procedures, Data, and Patient Management
Bariatric surgery comprises a group of operative procedures designed to improve weight-related medical conditions. In the United States, these include vertical sleeve gastrectomy, Roux-en-Y gastric bypass, adjustable gastric banding, and the duodenal switch procedure. Bariatric surgery is the only durable and effective way for most humans to lose a significant amount of weight, and see improvement in obesity-related comorbidities. It can improve quality of life, prevent a number of cancers, and decrease overall mortality.
Publication date: Available online 2 August 2019Source: The Lancet Diabetes &EndocrinologyAuthor(s): Jérémie Thereaux, Thomas Lesuffleur, Sébastien Czernichow, Arnaud Basdevant, Simon Msika, David Nocca, Bertrand Millat, Anne Fagot-CampagnaSummaryBackgroundConcerns are rising about the late adverse events following gastric bypass and sleeve gastrectomy. We aimed to assess, over a 7-year period, the late adverse events after gastric bypass and sleeve gastrectomy compared with matched control groups.MethodsIn this nationwide, observational, population-based, cohort study, we used data extracted from ...
Conclusions: Bariatric surgery appears to be capable of partially reversing the obesity-related epigenome. The identification of potential epigenetic biomarkers predictive for the success of bariatric surgery may open new doors to personalized therapy for severe obesity. Introduction Obesity is currently a huge healthcare problem, worldwide, and is a risk factor for several diseases such as type 2 diabetes (T2D), cardiovascular disease and cancer (1). As the prevalence of obesity reaches pandemic proportions, this metabolic disease is estimated to become the biggest cause of mortality in the near future (2). In fact,...
Bariatric surgery is the most effective therapy for patients with morbid obesity today . However, the types of operation are still evolving. Sleeve gastrectomy (SG) recently has quickly gained popularity as a primary bariatric surgery worldwide [2,3]. SG plus duodeno-jejunostomy (SG-DJB) was introduced in 2007 as an alternative to Roux-en-Y gastric bypass (RYGB) because the issue of gastric cancer arising from the excluded stomach . SG-DJB can be regarded as a modification of duodenal switch (DS) with short bypass limb and fewer nutritional problems .
Bariatric surgery is the most effective therapy for patients with morbid obesity today . However, the types of operation are still in evolving. Sleeve gastrectomy (SG) recently has quickly gained popularity as a primary bariatric surgery worldwide [2, 3]. SG plus duodeno-jejunostomy (SG-DJB) was introduced in 2007 as an alternative to Roux-en-Y gastric bypass (RYGB) because the issue of gastric cancer arising from the excluded stomach . SG-DJB can be regarded as a modification of duodenal switch (DS) with short bypass limb and fewer nutritional problems .
Background: Women of child-bearing potential generally experience an increase in fertility following bariatric surgery. However, the most commonly performed bariatric operations, Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (VSG), may impair absorption of oral contraceptives, potentially rendering them ineffective. Moreover, women desiring to lose weight should avoid contraceptive medications known to cause weight gain. As an alternative, bilateral salpingectomy provides highly reliable contraception and has even been proposed as a strategy to reduce the risk of ovarian, tubal, and peritoneal cancers.
CONCLUSION: Bariatric surgery is associated with decreased risk of hormone-related cancers, whereas gastric bypass might increase the risk of colorectal cancer. PMID: 30003539 [PubMed - as supplied by publisher]
Roux-en-Y gastric bypass (RYGB) improves comorbidities such as diabetes and hypertension and lowers the risk of obesity-related cancers. To better understand the physiologic and genetic influences of bariatric surgery, a reliable murine model is needed that can be extended to genetically engineered mice. Given the complexity of these procedures, few researchers have successfully implemented these techniques beyond larger rodent models. The purpose of our study was to develop a technically feasible and reproducible murine model for RYGB and sleeve gastrectomy (SG).
ConclusionThe current preliminary study thus identified potentially carcinogenic proteins in obese patients. Surgical weight loss resulted in the not detection of these proteins.
We present the case of a 55-year-old super-super obese man with a family history of GC and antral gastritis with extensive intestinal metaplasia at preoperative upper endoscopy, who underwent laparoscopic RYGBP with remnant gastrectomy. PMID: 29350665 [PubMed - in process]
ConclusionsAlthough both LSG and LSG/DJB have good antidiabetic effects in Japanese obese patients, LSG/DJB is more effective for patients with lower ABCD scores.